Document is current
Any future updates will be listed below
-
Authors
Rosenson, Robert S.
Chen, Qinzhong
Najera, Sherwin D.
Krishnan, Prakash
Lee, Martin L.
Cho, Daniel J.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02325466 at ClinicalTrials.govDocuments that mention this clinical trial
Ticagrelor improves blood viscosity-dependent microcirculatory flow in patients with lower extremity arterial disease: the Hema-kinesis clinical trial
https://doi.org/10.1186/s12933-019-0882-5
-
Funding
Funding for this research was provided by:
AstraZeneca (ISSBRIL0174, D5130L00060)
- License Information
-
More Information
Article History
Received: 27 March 2019
Accepted: 31 May 2019
First Online: 7 June 2019
Ethics approval and consent to participant
: The Institutional Review Board at the Icahn School of Medicine at Mount Sinai in New York, NY approved this study.
: The manuscript was submitted to the sponsor for review before submission. The analysis of data and decision to publish these data were the sole decision of the investigators.
: Dr. Rosenson receives grant funding from Akcea, Amgen, AstraZeneca, Medicines Company and Regeneron. At the time of funding for this trial, he attended an Advisory Board for AstraZeneca. He receives consulting fees and honoraria from Amgen, C5, CVS Caremark and Kowa; royalties from UpToDate, Inc. and holds stock in MediMergent LLC. Dr. Chen and Mr. Najera report no relevant conflicts of interest. Dr. Krishnan receives consultanting fees Medtronic and Abbott. Dr. Lee and Mr. Cho receive consulting fees from Rheovector LLC.
